Becton, Dickinson and Company provided earnings guidance for the fiscal year 2022. On a post-spin basis which reflects the former Diabetes Care business as discontinued operations in both the current and prior-year periods, the company provided the following guidance: The company expects fiscal year 2022 revenues to be in the range of approximately $18.5 billion to $18.7 billion. Revenue guidance for fiscal year 2022 assumes base business currency-neutral revenue growth of 7.25% to 8.25%.